131 related articles for article (PubMed ID: 7380205)
21. Ranitidine disposition in severe hepatic cirrhosis.
Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
[TBL] [Abstract][Full Text] [Related]
22. Pericellular collagen in alcoholics with liver cirrhosis.
Arranto AJ; Rautio A; Sotaniemi EA
Res Commun Chem Pathol Pharmacol; 1982 Jan; 35(1):121-35. PubMed ID: 7058284
[TBL] [Abstract][Full Text] [Related]
23. Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study.
Li CP; Lee FY; Hwang SJ; Chang FY; Lin HC; Kuo BI; Chu CJ; Lee SD
Am J Gastroenterol; 2000 Apr; 95(4):1051-5. PubMed ID: 10763958
[TBL] [Abstract][Full Text] [Related]
24. Furosemide disposition in cirrhotic patients.
Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
[TBL] [Abstract][Full Text] [Related]
25. Impairment of drug elimination in patients with liver disease.
Narang AP; Datta DV; Mathur VS
Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of furosemide in patients on peritoneal dialysis.
Flinn A; Ledger S; Blake P
CANNT J; 2006; 16(3):40-4. PubMed ID: 17061696
[TBL] [Abstract][Full Text] [Related]
27. [Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus].
Oltmanns D; Dennin DE; Pentz R; Siegers CP
Z Gastroenterol; 1984 Oct; 22(10):598-601. PubMed ID: 6506825
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (Catergen) in chronic alcoholic liver disease.
Pár A; Horváth T; Beró T; Kádas I; Pakodi F; Jávor T
Acta Physiol Hung; 1984; 64(3-4):449-54. PubMed ID: 6152369
[TBL] [Abstract][Full Text] [Related]
29. Sodium retention does not occur at a critical threshold of liver function in alcoholic cirrhosis.
Rector WG; Everson GT; Robertson AD
J Lab Clin Med; 1994 Feb; 123(2):218-24. PubMed ID: 8301197
[TBL] [Abstract][Full Text] [Related]
30. Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites.
Spahr L; Villeneuve JP; Tran HK; Pomier-Layrargues G
Hepatology; 2001 Jan; 33(1):28-31. PubMed ID: 11124817
[TBL] [Abstract][Full Text] [Related]
31. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.
Pérez-Ayuso RM; Arroyo V; Planas R; Gaya J; Bory F; Rimola A; Rivera F; Rodés J
Gastroenterology; 1983 May; 84(5 Pt 1):961-8. PubMed ID: 6339312
[TBL] [Abstract][Full Text] [Related]
32. Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone.
Abbas Z; Mumtaz K; Salam A; Jafri W
J Coll Physicians Surg Pak; 2003 Jul; 13(7):382-4. PubMed ID: 12887837
[TBL] [Abstract][Full Text] [Related]
33. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
[TBL] [Abstract][Full Text] [Related]
34. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
[TBL] [Abstract][Full Text] [Related]
35. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study.
Péron JM; Bureau C; Gonzalez L; Garcia-Ricard F; de Soyres O; Dupuis E; Alric L; Pourrat J; Vinel JP
Am J Gastroenterol; 2005 Dec; 100(12):2702-7. PubMed ID: 16393223
[TBL] [Abstract][Full Text] [Related]
36. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
Traeger A; Horváth T; Rechenbach C; Jávor T
Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
[TBL] [Abstract][Full Text] [Related]
37. Spironolactone and frusemide in cirrhosis with ascites.
Sadikali F
Br J Clin Pract; 1973 Jun; 27(6):222-4. PubMed ID: 4582147
[No Abstract] [Full Text] [Related]
38. Unresponsiveness of hepatic nitrogen metabolism to glucagon infusion in patients with cirrhosis: dependence on liver cell failure.
Fabbri A; Marchesini G; Bianchi G; Bugianesi E; Bortoluzzi L; Zoli M; Pisi E
Hepatology; 1993 Jul; 18(1):28-35. PubMed ID: 8325618
[TBL] [Abstract][Full Text] [Related]
39. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial.
Conchillo M; de Knegt RJ; Payeras M; Quiroga J; Sangro B; Herrero JI; Castilla-Cortazar I; Frystyk J; Flyvbjerg A; Yoshizawa C; Jansen PL; Scharschmidt B; Prieto J
J Hepatol; 2005 Oct; 43(4):630-6. PubMed ID: 16024131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
